Which Patients Are Eligible for Coverage?:

Beovu should be covered to treat patients with DME provided that Beovu is covered for a similar patient population and in a similar way to other anti–vascular endothelial growth factor (VEGF) drugs currently reimbursed by public drug plans for the treatment of adult patients with DME.

What Are the Conditions for Reimbursement?:

Beovu should only be reimbursed if prescribed by an ophthalmologist with experience in managing DME and if its cost is not more than the least costly anti-VEGF drug covered by the public drug plans for the treatment of DME.

Why Did CADTH Make This Recommendation?

• Evidence from 2 clinical trials demonstrated that Beovu is no worse than Eylea in maintaining or improving clearness or sharpness of vision in patients with DME.
• Patients with DME identified a need for new treatments that require fewer injections. Although there was not enough evidence that injections are less frequent with Beovu, approximately half of the patients treated with Beovu received it every 12 weeks (versus Eylea at every 8 weeks) after 52 weeks of treatment in both trials.
• Based on CADTH’s assessment of the health economic evidence, Beovu does not represent good value to the health care system at the public list price. There is not enough evidence to justify a greater cost for Beovu compared with other anti-VEGFs covered by the public drug plans for patients with DME.
• Based on public list prices, Beovu may decrease costs for the public drug plans; however, the actual budget impact is uncertain and will depend on the treatment frequency and which anti-VEGF drugs are displaced by Beovu.

What Is DME?:

DME is an eye disease caused by blood vessels leaking fluid into a part of the eye called the macula, which is responsible for sharp central vision and seeing fine detail. Untreated DME is a leading cause of visual loss, visual disability, and legal blindness in people with diabetes. It is estimated that 60,000 adults with DME in Canada experience vision impairment that requires treatment.

Unmet Needs in DME:

Patients with DME expressed a need for new treatments that are effective, less invasive, and require fewer administrations.

How Much Does Beovu Cost?:

Treatment with Beovu is expected to cost between $9,730 and $11,120 per patient in the first year of use (based on 7 to 8 injections) depending on how many injections are required. In subsequent years, the annual cost per patient is expected to be between $5,560 and $9,730 (based on 4 to 7 injections per year).

Input From the Clinical Expert Consulted by CADTH

The clinical expert consulted by CADTH indicated that the treatment goals of DME are to delay and, in some cases, reverse disease progression of DME and/or DR, as well as to improve vision-related and general quality of life. Considering that most patients are currently required to attend treatment visits once every 1 to 3 months, the clinical expert noted that there is an unmet need for treatments that can be given at longer treatment intervals, without recurrence of disease, to reduce the burden on patients and caregivers associated with frequent treatment visits and to increase adherence with treatment regimens.

The clinical expert noted that brolucizumab is expected to have a similar place in therapy to other anti-VEGFs, as a first line or as a later line of treatment in patients with DME. Treatment with brolucizumab is anticipated to reduce the burden of care by increasing the intervals between treatments but still maintain therapeutic benefit, when compared to other anti-VEGFs, which could potentially address the unmet need related to frequent treatment visits.

The clinical expert identified that patients with vision loss–associated DR secondary to centre-involving DME are suitable candidates for brolucizumab. The clinical expert indicated that brolucizumab can be used in patients who are treatment naive or those who require a change in therapy due to inadequate response to other anti-VEGF drugs. Patients who may not be suitable for treatment include those who present with major structural damage to the macular retina (e.g., macular atrophy or fibrosis), according to the expert.

The clinical expert noted that clinical evaluation and optical coherence tomography should be performed for prognosis and follow-up at dosing visits. Key assessment outcomes include change in visual acuity and retinal thickness, and the presence of retinal fluid. According to the expert, optimal response to anti-VEGFs is generally achieved at least 6 to 12 months after initiation of therapy.

The clinical expert indicated that brolucizumab should be discontinued in patients with treatment futility with proof of irreversible anatomic or functional damage, such as macular atrophy (schema) and fibrosis.

Regarding prescribing conditions, the clinical expert recommended retina subspecialty care as the most appropriate treatment setting for prescription and administration of brolucizumab in urban areas and trained comprehensive ophthalmologists with experience and expertise in managing DME as sufficient in rural settings.

Description of Studies

Two studies, KESTREL (N = 566) and KITE (N = 360), met the inclusion criteria for the systematic review section. They were similarly designed phase III RCTs that evaluated the noninferiority (based on an a priori noninferiority margin of −4 ETDRS letters) of brolucizumab (6 mg every 8 weeks or every 12 weeks during maintenance with every 16 weeks as an option after week 72 in the KITE trial) to aflibercept (2 mg every 8 weeks during maintenance) through the change from baseline in BCVA using ETDRS letters at week 52 in the full analysis set population as a primary end point. The dose frequency for brolucizumab was determined by disease activity as assessed by visual acuity and/or anatomic parameters. Patient demographic and disease characteristics were generally well balanced across the arms in both trials at baseline. The mean age of enrolled patients at baseline in these studies ranged from 62.2 years to 64.4 years, and the majority of patients were male (greater than 58%) and white (greater than 73%). The mean time since the diagnosis of DME was 9.4 months to 12.5 months in the KESTREL study and 9.9 months to 10.4 months in the KITE study; mean baseline retinal thickness in these 2 studies ranged from 453 μm to 484 μm; and the mean baseline BCVA score ranged from 63.7 letters to 66.6 letters in both studies, although in the KITE trial, there was an imbalance in the number of ETDRS letters (66.0 [standard deviation (SD) = 10.8] in the brolucizumab group and 63.7 [SD = 11.7] in the aflibercept group). All enrolled patients were anti-VEGF-naive. Outcomes included changes in BCVA, anatomic outcomes, DR severity, vision-related function, injection frequency, and safety, with a primary analysis at week 52, and data up to 100 weeks.

Efficacy Results

The results of KESTREL and KITE trials support the noninferiority of brolucizumab 6 mg (5 every 6 weeks loading doses followed by maintenance injections every 8 weeks or every 12 weeks) versus aflibercept 2 mg (5 monthly loading doses followed by maintenance injections every 8 weeks) for the change in BCVA. Noninferiority of brolucizumab 6 mg to aflibercept 2 mg was demonstrated for the primary end point (change from baseline in BCVA at week 52 for the study eye) using a noninferiority margin of 4 letters (P < 0.001 for noninferiority). The between-group LS mean difference for brolucizumab 6 mg versus aflibercept 2 mg in the KESTREL trial was −1.3 letters (95% CI, −2.9 to 0.3); the between-group LS mean difference in the KITE trial was 1.2 letters (95% CI, −0.6 to 3.1). In addition, several sensitivity analyses by the sponsor, as well as a supportive analysis using the per-protocol population, were consistent with the findings of the primary analyses. Results were consistent for change from baseline to week 100. Results of prespecified subgroup analyses (i.e., baseline BCVA categories and central subfield thickness [CSFT] categories) were generally consistent with the overall population at week 52; however, the study was not powered to detect subgroup differences. Noninferiority of brolucizumab 6 mg to aflibercept 2 mg was also demonstrated for the mean change from baseline in BCVA averaged over the period of week 40 through week 52.

The change in retinal thickness (measured with CSFT) from baseline and patients with CSFT lower than 280 μm were secondary outcomes in the studies. According to the expert, the reduction in retinal thickness correlates well to the improvement in visual acuity. In the KESTREL trial, the LS mean difference in the change from baseline in CSFT between the brolucizumab 6 mg arm and the aflibercept 2 mg arm was −5.1 µm (95% CI, −22.3 µm to 12.2 µm). Over the period of week 40 through week 52, the average LS mean of the change from baseline in CSFT between brolucizumab 6 mg and aflibercept 2 mg was −1.4 µm (95% CI, −17.9 µm to 15.0 µm). In the KITE trial, the LS mean difference in the change from baseline in CSFT to week 52 between the brolucizumab 6 mg arm and the aflibercept 2 mg arm was −32.8 µm (95% CI, −52.5 µm to −13.0 µm). Over the period of week 40 through week 52, the average LS mean of the change from baseline in CSFT between brolucizumab 6 mg and aflibercept 2 mg was −29.4 µm (95% CI, −48.6 µm to –10.2 µm; P = 0.001) in favour of brolucizumab. These differences between brolucizumab and aflibercept were similar at year 2.

The change from baseline in National Eye Institute Visual Functioning Questionnaire–25 (NEI-VFQ-25) composite score, which measures vision-related functions and some aspects of HRQoL, was a secondary outcome in the KESTREL and KITE trials, but not included in the statistical hierarchy. In the KESTREL study, the between-group LS mean differences for the change from baseline were −1.0 (95% CI, −3.4 to 1.4) at week 52 and −0.2 (95% CI, −2.9 to 2.6) at week 100. In the KITE study, the between-group LS mean differences for the change from baseline were 2.5 (95% CI, 0.2 to 4.8) at week 52 and 3.4 (95% CI, 0.8 to 6.1) at week 100.

ETDRS Diabetic Retinopathy Severity Scale score was used to measure disease activity in patients with DME. Regression of Diabetic Retinopathy Severity Scale score is another clinically meaningful outcome in this study population; however, this outcome was not included in the statistical hierarchy. For most of the results for this outcome at week 52 and week 100, there was no evidence to suggest a difference between brolucizumab and aflibercept. Given the uncertainty in the analysis due to lack of statistical testing and imprecision in the between-group differences, no definite conclusions on the change in disease severity can be drawn.

The pivotal trials measured the proportions of patients with presence of IRF and SRF as secondary outcomes. IRF and SRF are indicators of active disease noted with care by clinicians on the qualitative assessment of the optical coherence tomography. According to the clinical expert consulted by CADTH, IRF is a more relevant outcome than SRF in patients with DME as SRF is uncommon in DME and is a marker for more severe DME. This outcome was not tested statistically due to a previous failure of the hierarchical testing procedure. A numerically lower proportion of patients treated with brolucizumab had the presence of IRF and/or SRF compared to the aflibercept group in both studies at week 52 and week 100.

Frequency of injection was noted to be an important outcome of interest by both patients and the clinical expert as it may have implications on frequency of adverse events (AEs), HRQoL, burden of treatment, and patient adherence, and subsequently can have an impact on the treatment effect. The proportion of patients treated with brolucizumab maintained on an every 12 weeks schedule was reported descriptively in the studies. At week 52, approximately half of this subgroup of patients maintained the every 12 weeks regimen||||||||||||||||||||||||||||||||||||||||||||| |||||||||| in the KESTREL and KITE trials, respectively. Among patients who completed treatment with brolucizumab at week 100, the majority of them were on an every 8 weeks regimen (67.1% in the KESTREL trial; 52.5% in the KITE trial).

Harms Results

The safety profile of brolucizumab 6 mg, was generally consistent with that of aflibercept 2 mg in the KESTREL and KITE trials. The proportion of patients reporting at least 1 ocular AE in the study eye up to week 100 was comparable across treatment arms in both studies (the KESTREL study = 48.7% and 50.3% in the brolucizumab 6 mg and aflibercept 2 mg group, respectively; the KITE study = 40.8% and 40.9% in the brolucizumab 6 mg and aflibercept 2 mg group, respectively). Overall, the most frequently reported ocular AEs related to brolucizumab in both studies were cataract, conjunctival hemorrhage, vitreous detachment, vitreous floaters, increased intraocular pressure, diabetic retinal edema, dry eye, eye pain, posterior capsule opacification, conjunctivitis, and reduced visual acuity. Cataract was reported as the most commonly reported ocular AE, which was anticipated because of the age of the study populations. Ocular serious AEs were reported with low frequency and similar between the 2 treatment groups in both studies (3.7% and 2.7% of patients in the KESTREL trial and 2.8% and 1.7% of patients in the KITE trial in the brolucizumab 6 mg group and aflibercept 2 mg group, respectively). The incidence of withdrawals due to AEs was also similar between the 2 treatment groups: (1.6% and 1.1% of patients in the KESTREL trial and 2.8% and 2.2% of patients in the KITE trial in the brolucizumab group compared with the aflibercept group, respectively). There were 15 deaths in the KESTREL study, 8 (4.2%) in the brolucizumab group and 7 (3.7%) in the aflibercept group. In the KITE study, 13 (7.3%) deaths occurred in the brolucizumab group and 9 (5.0%) in the aflibercept group. According to the sponsor, none of the deaths were related to the study treatment.

Critical Appraisal

KESTREL and KITE were similarly designed randomized, double-masked, active-controlled, noninferiority phase III trials comparing brolucizumab (6 mg in both studies, 3 mg in the KESTREL trial only) to aflibercept (2 mg). The overall designs of the KESTREL and KITE trials were appropriate for the objectives of the studies. There were no major concerns with regards to the method of randomization, stratification, allocation concealment, and masking for randomized assignment. The baseline characteristics of the study population were generally well balanced between treatment arms and across studies, with the exception that patients in the KITE study had a relatively large imbalance in the number of ETDRS letters between the 2 treatment arms, somewhat thicker retina at baseline, and were more likely to receive prior ocular medications compared to those enrolled in the KESTREL study. However, the clinical expert thought that these differences were unlikely to impact the results between the studies.

In the KESTREL and KITE trials, the results of change from baseline in BCVA at week 52 using the per-protocol population were consistent with those in the full analysis set. In both studies, sensitivity analyses were conducted to assess the robustness of the hypothesis testing that resulted from the primary analysis. Various methods were used to account for missing data, such as the mixed models for repeated measures modelling assuming a missing at random mechanism, or the last observation carried forward approach. The missing at random assumption may be a concern, given that the primary reasons for discontinuation from the study included patient decision, death, and AEs. Furthermore, the last observation carried forward method assumes that patient outcomes do not change after they drop out, which may not hold true in practice. Therefore, additional sensitivity analyses that did not assume that missing data were missing at random could be useful. However, the results of the sensitivity analyses confirmed those of the primary analysis, suggesting these approaches in handling missing data were unlikely to introduce bias in the primary end point. Risk of attrition bias due to missing data was of particular concern for the NEI-VFQ-25 as there was more than 20% missing data for some treatment groups.

A statistical hierarchy was used for multiplicity adjustment for selected outcomes. Some important outcomes were not included in the hierarchy, such as vision-related HRQoL assessed by NEI-VFQ-25, change in retinal thickness, or change in DR severity. In addition, the statistical hierarchy failed relatively early on at some points. In the KESTREL trial, noninferiority of brolucizumab 3 mg to aflibercept 2 mg was not achieved at week 52. As per the study protocol, confirmatory testing did not proceed to assess the superiority of brolucizumab versus aflibercept for the outcomes that followed in the hierarchical testing procedure, which limits drawing definite conclusions on these outcomes.

Based on the patient’s baseline characteristics, the study population in the KESTREL and KITE trials may not fully represent the typical population of patients with DME in Canada who would be receiving anti-VEGF therapy. The clinical expert consulted by CADTH indicated that the inclusion criteria of the KESTREL and KITE trials were reasonable and reflective of the eligibility criteria for anti-VEGF treatment in clinical practice. Although all patients enrolled in the KESTREL and KITE trials were anti-VEGF naive, and exhaustive exclusion criteria were used in the 2 studies, the clinical expert indicated that brolucizumab can be used in a broader population, such as for those with poor glycemic control or those who have received a previous anti-VEGF therapy.

In the 2 pivotal studies, patients in the brolucizumab group could have their dosing interval extended, reduced, or maintained postrandomization based on the assessments of disease activity. Once patients on brolucizumab dropped back to every 8 weeks because of disease activity, they could not extend the treatment interval for the rest of the study, which may contradict clinical practice. Changes in treatment interval and dosage were not allowed for treatment with aflibercept, and these patients remained on a fixed every 8 weeks interval during the maintenance phase; this is contrary to clinical practice as the product monograph of aflibercept states that the treatment interval can be extended after the first year of treatment. According to the clinical expert, patients in the real world may not receive as many loading doses as in the clinical trial and it is possible that the outcomes observed in practice could differ from those shown in the clinical trials.

Description of Studies

The sponsor-submitted ITC provided indirect evidence on the efficacy and safety of brolucizumab relative to other anti-VEGFs for adult patients with DME. The active comparators for brolucizumab included aflibercept, ranibizumab, and bevacizumab. Relevant RCTs were identified through a systematic literature search, and 43 RCTs were included in the NMA. Outcomes of change in BCVA, retinal thickness, change in disease activity, study discontinuation, and safety were evaluated in the study population. A Bayesian NMA approach was taken for data synthesis.

Efficacy Results

The sponsor-submitted NMA provided indirect comparative evidence for brolucizumab versus other anti-VEGF drugs. After including 43 trials in an NMA, none of the treatments was favoured when brolucizumab was compared with other active treatments, such as aflibercept, ranibizumab or bevacizumab for the treatment of DME, in improving visual acuity and lessening disease severity. For most comparisons, the effect estimate was too imprecise (i.e., wide 95% credible interval [CrI]) to draw a conclusion about the comparative effects. Treatment with brolucizumab was associated with more reduction in retinal thickness than bevacizumab or ranibizumab. In addition, the ITC results suggested that patients treated with brolucizumab may receive fewer injections compared to those treated with other anti-VEGFs, though these results were derived from a naive comparison rather than an NMA and should be particularly interpreted with caution. The key limitations for the ITC are significant heterogeneity across the included RCTs (in study design and patient characteristics) and imprecision around the effect estimates (i.e., wide 95% CrIs), which precluded drawing a conclusion for most outcome comparisons. This limits the conclusions that can be drawn from this ITC.

Harms Results

The risks of ocular AEs, nonocular AEs, and study discontinuation were evaluated in the NMA. The results suggested that none of the treatments was favoured for reduction in the risk of ocular or nonocular-ocular AEs. For all comparisons, the effect estimate was too imprecise (i.e., wide 95% CrIs) to draw a conclusion about the comparative effects. Limitations to the NMA preclude making firm conclusions about relative risks of harm for brolucizumab compared to other anti-VEGFs.

Critical Appraisal

In the sponsor-provided ITC, the degree of heterogeneity between the included studies was difficult to assess because of incomplete reporting of study characteristics (such as patients’ disease characteristics at baseline). Description of trial design, sample size, and disease duration were reported; however, the ITC failed to report information related to the methods used for handling missing data. There was considerable variability in study design, year of conduct, sample size, and treatment regimen. The risk of bias in the included trials was assessed using a checklist from the National Institute for Health and Care Excellence (NICE), but further details on how risk of bias assessment was carried out were not provided.

Similarly, inadequate information about baseline patient characteristics as well as variability in baseline patient characteristics contribute to heterogeneity in the studies included in the ITC. Clinical trial eligibility criteria were described for the trials ultimately included in the NMA; however, many individual studies failed to report or inadequately reported patient characteristics, resulting in gaps in the extracted ITC data. There was a lack of information about key baseline characteristic such as the presence of significant diabetic macular ischemia, previous treatment and patient’s response, IRF, and systemic comorbidities, including hypertension, chronic kidney disease, obesity, or cardiac conditions.

Most of the patients’ baseline characteristics were presented graphically. Even though some of the patients’ baseline characteristics were comparable, for example age (ranged from 58 to 66 years) and hemoglobin A1C level (ranged from 7.3 to 8.7), heterogeneity still exists. The mean time since diagnosis of DME ranged from 1.2 to 3.4 years. The duration of diabetes ranged from 10 to 18 years in the included studies. Based on data from 26 trials, the mean BCVA scores ranged from 33 to 71 letters. Based on data from 25 trials, the mean retinal thickness at baseline ranged from 321 µm to 596 µm, and the majority of studies included patients with a retinal thickness of more than 400 µm. There was also heterogeneity in the reporting of methods for measuring and in results of changes in retinal thickness. Based on heterogeneity in the factors that were reported and the inability to assess those that were not reported, there is considerable uncertainty whether the assumptions related to homogeneity were met. The treatment effect of the study drug could differ by patient characteristics at baseline. Despite acknowledging the degree of heterogeneity, the technical report did not provide sufficient information of assessments of heterogeneity (e.g., graphic representation of baseline characteristics, statistical tests) to fully understand the sources of heterogeneity. Therefore, the potential for heterogeneity to have influenced the comparative efficacy and safety estimates is plausible, and it is not possible to quantify or identify the direction of the bias. Several assumptions were made when defining treatment node assignment; for example, the different dose does not impact the outcomes, and similar efficacy was assumed between the ranibizumab 0.3 mg and 0.5 mg doses, or there were no significant differences in the effect of different regimens (aflibercept every 4 weeks, every 8 weeks, or as needed). It is uncertain if these assumptions are valid.

For injection frequency, brolucizumab every 8 weeks and every 12 weeks were examined in the ITC. Data were pooled without conducting an NMA. Although drug administration with fixed treatment intervals according to the protocol are commonly observed in clinical trials, the clinical expert consulted by CADTH indicated that in the real world, treatment regimens could be more flexible based on a patient’s response. Therefore, the findings from clinical trials may not reflect the clinical practice.

Description of Study

One multicentre, randomized, double-masked, active-controlled, parallel group, prospective, phase III study (KINGFISHER) was conducted to evaluate the efficacy and safety of brolucizumab versus aflibercept in the treatment of adult patients with visual impairment due to DME. The primary objective was to demonstrate that brolucizumab was noninferior to aflibercept with respect to change in visual acuity from baseline up to week 52.

A total of 346 and 171 patients were randomized to brolucizumab 6 mg administered every 4 weeks and aflibercept 2 mg administered every 4 weeks, respectively. The 48-week double-masked treatment period was followed by a 4-week follow-up period of up to week 52. Patients were evaluated every 4 weeks for the duration of the study. Only 1 eye was selected as the study eye and treated with the study drug. Study discontinuation rates were 10.1% and 8.8% in the brolucizumab and aflibercept arms, respectively. A total of 189 patients (54.6%) in the brolucizumab arm and 94 patients (55.0%) in the aflibercept arm received all 13 injections following the every 4 weeks regimen.

The inclusion and exclusion criteria used in the KINGFISHER study were generally consistent with the eligibility criteria used in the pivotal KESTREL and KITE studies. The KINGFISHER trial included adult patients with diabetes mellitus type 1 or type 2 who were diagnosed with visual impairment due to DME. Of note, patients could either be treatment naive or have previously received an anti-VEGF therapy but could not have received any injections within the 3-month period before baseline.

The mean age of patients was 60.9 years (SD = 10.59) in the brolucizumab arm and 60.2 years (SD = 9.31) in the aflibercept arm. There was a higher proportion of males than females in both arms (56.1% in the brolucizumab arm and 61.4% in the aflibercept arm). The mean duration of diagnosis with DME was 20.6 months (SD = 29.94) and 18.2 months (SD = 25.60) in the brolucizumab and aflibercept arms, respectively. The mean BCVA letters score was 61.3 (SD = 10.14) and 60.5 (SD = 11.27) in the brolucizumab and aflibercept arms, respectively. The mean CSFT was 514.1 μm (SD = 138.94 μm) and 511.2 μm (SD = 156.29 μm) in the brolucizumab and aflibercept arms, respectively. Most patients in both treatment arms had mild to moderately severe nonproliferative DR (75.6% [n = 167] and 76.3% [n = 90] in the brolucizumab and aflibercept arms, respectively). Prior anti-VEGF treatment in the study eye was reported in 95 patients (27.5%) and 52 patients (30.4%) in the brolucizumab and aflibercept arms, respectively.

Harms Results

A total of 105 patients (30.3%) in the brolucizumab arm and 59 patients (34.5%) in the aflibercept arm reported at least 1 ocular AE. The most common ocular AE reported in the brolucizumab arm was vitreous detachment in 10 patients (2.9%). A total of 3 patients (0.9%) in the brolucizumab arm reported at least 1 serious ocular AE; vitreous hemorrhage in 2 patients (0.6%), and cataract subcapsular and retinal vasculitis in 1 patient (0.3%) each. No patients in the aflibercept arm reported any serious ocular AE. A total of 7 patients (2.0%) and 3 patients (1.8%) withdrew from study treatment in the brolucizumab and aflibercept arms, respectively, due to an ocular AE, with the most common ocular event documented as related to an eye disorder (6 patients [1.7%] and 3 patients [1.8%], respectively).

Intraocular inflammation was reported in 14 patients (4.0%) in the brolucizumab arm versus 5 patients (2.9%) in the aflibercept arm. Retinal vasculitis was reported in 3 patients (0.9%) in the brolucizumab arm versus 1 patient (0.6%) in the aflibercept arm. Retinal vascular occlusion was reported in 1 patient in each arm (0.3% versus 0.6% in brolucizumab and aflibercept arms, respectively). Arterial thromboembolic events were reported in 15 patients (4.3%) in the brolucizumab arm versus 9 patients (5.3%) in the aflibercept arm. Increased transient intraocular pressure was reported in 3 patients (0.3%) in the brolucizumab arm versus 2 patients (1.2%) in the aflibercept arm. No reports of endophthalmitis were recorded.

Critical Appraisal

The trial was at low risk of bias due to randomization; the 2 arms were generally balanced with respect to baseline demographic and disease characteristics. The trial was double masked; however, there was some potential for unmasking because the personnel providing the injections were aware of the assigned treatment. The likelihood of unmasking and potential for bias in the reporting of subjective outcomes (i.e., some harms) is uncertain. The trial was powered for the safety assessment according to FDA recommendations. Attrition was relatively low and balanced across the arms, suggesting a low risk of attrition bias.

The clinical expert consulted by CADTH for this review advised that the results of the KINGFISHER trial would not be generalizable to the patient population in Canada and to Canadian clinical practice because the frequency of administration (i.e., every 4 weeks) is not a relevant treatment interval. Furthermore, aflibercept is rarely administered every 4 weeks in clinical practice.